Ranganathan L N, Ramaratnam S
Stanley Medical College, Department of Neurology, Chennai, Tamil Nadu, INDIA, 600014.
Cochrane Database Syst Rev. 2006 Apr 19(2):CD005003. doi: 10.1002/14651858.CD005003.pub2.
The ideal objective of treating a person with epilepsy is to induce remission by usage of antiepileptic drugs (AEDs) and withdraw the AEDs without causing seizure recurrence. Prolonged usage of AEDs may have long-term side effects. Hence when a person with epilepsy is in remission (free of seizures for some time) it is logical to attempt to discontinue the medication. The timing of withdrawal and the mode of withdrawal arise while contemplating withdrawal of AEDs. This review proposes to examine the evidence for the rate of withdrawal of AEDs (whether rapid or slow tapering) and its effect on recurrence of seizure. This review also examines the effect of variables such as age of seizure onset, seizure types, presence of neurological deficits, mental subnormality, aetiology of epilepsy, type of AED, EEG findings or duration of seizure freedom on the risk of recurrence of seizures with the two tapering regimens.
(1) To quantify risk of seizure recurrence after rapid (taper period of three months or less) or slow (taper period or more than three months) discontinuation of antiepileptic drugs in adults with epilepsy who are in remission. (2) To quantify the risk of seizure recurrence after rapid (taper period of three months or less) or slow (taper period of more than three months) discontinuation of antiepileptic drugs in children with epilepsy who are in remission. (3) To attempt to assess which variables modify the risk of seizure recurrence.
We searched the Cochrane Epilepsy Group's Specialized Register (August 2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2005), MEDLINE (1966 to September 2004) and cross-references from identified studies. No language restrictions were imposed.
Randomized controlled trials that evaluate withdrawal of AEDs in a rapid or slow manner after varying periods of seizure control in patients with epilepsy.
Both review authors independently assessed the trials for inclusion and extracted the data. The outcomes assessed included seizure relapse (i.e. the percentage of patients experiencing seizure recurrence after withdrawal of AED); time to recurrence of seizure following withdrawal; occurrence of status epilepticus; mortality; morbidity due to seizure such as injuries, fractures, aspiration pneumonia; and quality of life (if assessed by validated scale).
One trial with weak methodology involving 149 children was included with a mean age of seizure onset of four years, mean age of 11 years at the time of starting the taper. The rapid taper group (six weeks) recruited 81 participants and the slow taper group (nine months) included 68 participants, out of whom 11 and 5 were lost to follow up even before the taper began respectively. The number of participants who were seizure free in the rapid and slow taper groups were 40 and 44 respectively at the end of one year follow up (OR 0.53, 95% CI 0.27 to 1.03); 30 and 29 respectively at the end of two years, (OR 0.79, 95% CI 0.41 to 1.53); 24 and 14 respectively at the end of three years (OR 1.62, 95% CI 0.76 to 3.46); 18 and 8 respectively at the end of four years (OR 2.14, 95% CI 0.87 to 5.3); 10 and 6 respectively at the end of five years (OR 1.46, 95% CI 0.5 to 4.23).
AUTHORS' CONCLUSIONS: In view of methodological deficiencies and small sample size, in the solitary study identified, we cannot derive any reliable conclusions regarding the optimal rate of tapering of AEDs. Further studies are needed in adults as well as in children to investigate the rate of withdrawal of AEDs and to study the effects of variables such as seizure types, its aetiology, mental retardation, EEG abnormalities, presence of neurological deficits and other co-morbidities on the rate of tapering.
治疗癫痫患者的理想目标是通过使用抗癫痫药物(AEDs)诱导缓解,并在不引起癫痫复发的情况下停用AEDs。长期使用AEDs可能会产生长期副作用。因此,当癫痫患者处于缓解期(一段时间无癫痫发作)时,尝试停药是合理的。在考虑停用AEDs时,出现了停药时机和停药方式的问题。本综述旨在研究AEDs停药速度(快速或缓慢减量)的证据及其对癫痫复发的影响。本综述还研究了诸如癫痫发作起始年龄、癫痫发作类型、神经功能缺损的存在、智力发育迟缓、癫痫病因、AED类型、脑电图结果或无癫痫发作持续时间等变量对两种减量方案癫痫复发风险的影响。
(1)量化缓解期成年癫痫患者快速(减量期三个月或更短)或缓慢(减量期超过三个月)停用抗癫痫药物后癫痫复发的风险。(2)量化缓解期儿童癫痫患者快速(减量期三个月或更短)或缓慢(减量期超过三个月)停用抗癫痫药物后癫痫复发的风险。(3)试图评估哪些变量会改变癫痫复发的风险。
我们检索了Cochrane癫痫小组专门注册库(2005年8月)、Cochrane对照试验中心注册库(CENTRAL)(Cochrane图书馆2005年第3期)、MEDLINE(1966年至2004年9月)以及已识别研究的交叉参考文献。未设语言限制。
评估癫痫患者在不同癫痫控制期后快速或缓慢停用AEDs的随机对照试验。
两位综述作者独立评估试验是否纳入并提取数据。评估的结果包括癫痫复发(即停用AEDs后癫痫复发患者的百分比);停药后癫痫复发的时间;癫痫持续状态的发生;死亡率;癫痫导致的发病率,如损伤、骨折、吸入性肺炎;以及生活质量(如果通过有效量表评估)。
纳入了一项方法学较弱的试验,涉及149名儿童,癫痫发作起始的平均年龄为4岁,开始减量时的平均年龄为11岁。快速减量组(六周)招募了81名参与者,缓慢减量组(九个月)包括68名参与者,其中分别有11名和5名在减量开始前就失访了。在一年随访结束时,快速和缓慢减量组无癫痫发作的参与者数量分别为40名和44名(OR 0.53,95% CI 0.27至1.03);两年结束时分别为30名和29名(OR 0.79,95% CI 0.41至1.53);三年结束时分别为24名和14名(OR 1.62,95% CI 0.76至3.46);四年结束时分别为18名和8名(OR 2.14,95% CI 0.87至5.3);五年结束时分别为10名和6名(OR 1.46,95% CI 0.5至4.2)。
鉴于所识别的唯一研究存在方法学缺陷和样本量小的问题,我们无法得出关于AEDs最佳减量速度的任何可靠结论。需要在成人和儿童中进行进一步研究,以调查AEDs的停药速度,并研究癫痫发作类型、病因、智力发育迟缓、脑电图异常、神经功能缺损的存在以及其他合并症等变量对减量速度的影响。